Combination Therapy with Diquafosol Tetra sodium and Sodium Hyaluronate in Patients with Dry Eye after Laser in Situ Keratomileusis

Combination Therapy with Diquafosol Tetra sodium and Sodium Hyaluronate in Patients with Dry Eye after Laser in Situ Keratomileusis. Prospective, Randomized, comparative, clinical trial.

Article Specifications

This clinical trial was published in 2014 in American journal of ophthalmology (IF 2014:6.1) by Japanese ophthalmologists. In this article 105 patients were randomly assigned in 4 groups: (1) 50 eyes of 25 patients to the artificial tear group, (2)46 eyes of 23 patients to the hyaluronate group, (3) 60 eyes of 30 patients to the diquafosol group, (4) 50 eyes of 27 patients to the combination group. Questionnaire responses reflecting subjective dry eye symptoms, uncorrected and corrected visual acuity, functional visual acuity, manifest refraction, tear break-up time, fluorescein corneal staining, Schirmer test, and corneal sensitivity were examined before and 1 week and 1 month after Lasik.

Results

In this article the combination therapy with diquafosol and hyaluronate for dry eye in patients after LASIK has been evaluated. The subjective symptom dryness and ocular fatigue scores in the hyaluronate, diquafosol, and combination groups were lower than in the artificial tear group at 1 week, and the difference was significant for both symptoms only in the combination group. Combination therapy can be beneficial to accelerate the recovery of dry eye symptoms. The Schirmer value was significantly higher in the combination group, suggesting that recovery of tear function was enhanced by hyaluronate and diquafosol combination therapy. In conclusion, combination therapy with hyaluronate and diquafosol improved tear secretion and dry eye symptoms after LASIK faster than monotherapy with either agent, effectively stabilizing vision.